CytomX gains Fast Track status for colorectal cancer antibody-drug conjugate
At a glance
- $CTMX today−2.27%last $1.94
- Vs industry peers−1.41 pts6-peer median −0.85% · behind
- Since Aug 27−39.6%from the first trade after the story
- 52-week range2.1% above low$1.90 – $8.21
- Cash runway~11 mo$34.0M cash ÷ $3.0M/mo burn · 10-Q
- Sector scannerCalmHealth Care
Nothing reported about cytomx across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: Healthcare upside usually comes in discrete events — readouts, approvals and launches — rather than gradual trends.
- How the stock is trading: $CTMX -2.27% in the latest session.
- Timing: It came out during market hours, so traders could react the same day, and the session move may reflect that.
Where the stock stands
CytomX Therapeutics ($CTMX) declined 2.27% to $1.94 in the latest session. Over the past month it is down 17.1%. It now sits 76% under the 52-week high of $8.21 and 2.1% above the year's low of $1.90, close to the bottom of its range. The year's high was 4.3 times its low, which makes double-digit swings fairly routine here.
What the filings say
In its latest report (10-Q, filed Nov 5, 2026), $CTMX lost $20.0M over the quarter to Sep 30, 2026 on revenue of $1.7M (+19.0% QoQ). Operations used $27.0M of cash over the nine months to Sep 30, 2026 — about $3.0M a month — against $34.0M in cash on Sep 30, 2026. At that pace the cash covers about 11 months, which is why financing, asset sales or restructuring tend to come up for companies in this position. Total liabilities were $79.8M against $34.0M of cash on Sep 30, 2026. Its most recent filings before this story: 8-K on Aug 6, 2026, 10-Q on Aug 6, 2026, 8-K on Jul 27, 2026. Figures are as filed with the SEC; the $CTMX page has the full statements.
How much coverage it is getting
Nothing new on these companies has come through Wook's feeds in the last 30 days, so this is still the most recent story on it.
The bigger picture
Healthcare stories turn on approvals, trial data and pricing: one FDA decision or trial readout can swing a single drugmaker hard, while drug-pricing policy moves the whole group at once. Health Care reads calm on Wook's supply-chain scanner today, with no unusual stress in the filings and disclosures it watches.
What to watch next
The company's own filings are the primary source. Its latest SEC reports, including any filing on a material event, are on the $CTMX page, and they say what management has disclosed without a reporter in between. Reading how two or three outlets frame the same story is the quickest way to separate the facts from the angle. To run the numbers yourself, ask Wook AI above about $CTMX: its distance from the high, its last report, or how coverage has changed.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Seeking Alpha published this on August 27, 2026. $CTMX has moved -39.56% ($3.21 to $1.94). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
